The Indian Journal of Pediatrics

, Volume 67, Issue 4, pp 299–300 | Cite as

Routine hepatitis B immunisation in India: Cost-effectiveness assessment



Based on World Bank guidelines, hepatitis B immunization would be an excellent public health investment, saving each life year for well below the per-capita gross domestic product. This would be one of the most cost-effective investments india could make in the field of health.

Key words

Hepatitis B immunization Cost-effectiveness 


  1. 1.
    World Health Assembly Resolution WHA 45.17 Immunization and vaccine quality. Geneva, May 4–14, 1992.Google Scholar
  2. 2.
    Nayak NC, Panda SK, Zuckerman AJ, Bhan MK, Guha DK. Dynamics and impact of perinatal transmission of hepatitis B virus in North India.J Med Virol 1987; 21 (2): 137–45.PubMedCrossRefGoogle Scholar
  3. 3.
    Dutta RN, Dutta AK. Prevalence of Australia antigen and antibody and its subtypes in India.J Indian Med Assoc 1977; 69 (8): 165–70.PubMedGoogle Scholar
  4. 4.
    Tandon BN, Irshad M, Raju M, Mathur GP, Rao MN. Prevalence of HBsAg and anti-HBs in children and strategy suggested for immunisation in India.Indian J Med Res 1991; 93: 337–9.PubMedGoogle Scholar
  5. 5.
    Singhvi A, Pulimood RB, John TJet al. The prevalence of markers for hepatitis B and human immunodeficiency viruses, malarial parasites and microfilaria in blood donors in a large hospital in South India.J Trop Med Hyg 1990; 93 (3): 178–82.PubMedGoogle Scholar
  6. 6.
    Pal SR, Chitkara NL, Choudhury S, Dutta DV, Deodhar SD, Chhuttani PN. Hepatitis B virus infection in northern India. Prevalence, subtypes., and seasonal variation.Bull WHO 1974; 51 (1): 13–7.PubMedGoogle Scholar
  7. 7.
    Irshad M, Joshi YK, Acharya SK, Tandon BN. Prevalence of hepatitis B virus infection in healthy persons in North India.Natl Med J India 1994; 7 (5): 210–2.PubMedGoogle Scholar
  8. 8.
    Nanu A, Sharma SP, Chatterjee K, Jyoti P. Markers for transfusion-transmissible infections in north Indian voluntary and replacement blood donors: prevalence and trends 1989–1996.Vox Sang 1997; 73 (2): 70–3.PubMedCrossRefGoogle Scholar
  9. 9.
    Beasley RP, Hwang L-Y. Epidemiology of hepatocellular carcinoma. In: Vyas GN, Dienstag JL, Hoofnagle JH (eds).Viral Hepatitis and Liver Disease. Orlando, Fla., Grune and Stratton 1984; 209–224.Google Scholar
  10. 10.
    Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma.Cancer 1988; 61: 1942–56.PubMedCrossRefGoogle Scholar
  11. 11.
    Szmuness W, Stevens CE, Harley EJet al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States.N Engl J Med 1980; 303 (15): 833–41.PubMedCrossRefGoogle Scholar
  12. 12.
    World Bank. World Development Report 1993: Investing in Health. New York: Oxford University Press. 1993.Google Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2000

Authors and Affiliations

  1. 1.National Institute of HealthBethesdaUSA
  2. 2.Bill and Melinda Gates Children’s Vaccine ProgramSeattleUSA

Personalised recommendations